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Abstract
Background: The major concern in liver transplantation of grafts from donation after circulatory death (DCD)
donors remains the high incidence of non-anastomotic biliary strictures (NAS). Machine perfusion has been
proposed as an alternative strategy for organ preservation which reduces ischemia-reperfusion injury (IRI).
Experimental studies have shown that dual hypothermic oxygenated machine perfusion (DHOPE) is associated with
less IRI, improved hepatocellular function, and better preserved mitochondrial and endothelial function compared
to conventional static cold storage (SCS). Moreover, DHOPE was safely applied with promising results in a recently
performed phase-1 study. The aim of the current study is to determine the efficacy of DHOPE in reducing the
incidence of NAS after DCD liver transplantation.
Methods: This is an international multicenter randomized controlled trial. Adult patients (≥18 yrs. old) undergoing
transplantation of a DCD donor liver (Maastricht category III) will be randomized between the intervention and
control group. In the intervention group, livers will be subjected to two hours of end-ischemic DHOPE after SCS
and before implantation. In the control group, livers will be subjected to care as usual with conventional SCS only.
Primary outcome is the incidence of symptomatic NAS diagnosed by a blinded adjudication committee. In all
patients, magnetic resonance cholangiography will be obtained at six months after transplantation.
Discussion: DHOPE is associated with reduced IRI of the bile ducts. Whether reduced IRI of the bile ducts leads to
lower incidence of NAS after DCD liver transplantation can only be examined in a randomized controlled trial.
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Background
Limited organ availability for liver transplantation re-
mains a major concern [1]. Utilization of livers with sub-
optimal quality or so called “extended criteria” donors,
such as older donors, donors with fatty livers and dona-
tion after circulatory death (DCD) donors, have reduced
the organ deficit in recent years. In fact, the percentage
of DCD donors in the USA has increased from 1.1% in
1995 to 11.2% in 2010 [2]. In Europe, the percentage of
DCD in liver transplantation was as high as 35% in the
Netherlands and 22% in the UK in 2015 [3, 4]. The poor
post-transplant outcomes of these grafts have concur-
rently limited the utilization of these livers. The percent-
age of unused grafts increased from 9% in 2004 to 28%
in 2010 in the USA which is mainly attributed to the
growing number of DCD donors [2].
Non-anastomotic biliary strictures (NAS) are a major
complication after liver transplantation and occur in
29% of patients receiving a DCD donor graft, compared
to 11% among recipients of donation after brain death
(DBD) liver grafts in the University Medical Center Gro-
ningen (unpublished data). Moreover, longer hospital
stay and increased cost have been associated with NAS
in DCD liver transplantation [5–7]. Among the variety
of risk factors described to be associated with NAS, is-
chemia/reperfusion related injury is one of the most im-
portant factors. Donor warm ischemia and cold ischemia
during static cold storage (SCS) have been associated
with the development of NAS after DCD [6, 8]. Also, in-
jury of the peribiliary vascular plexus and peribiliary
glands is thought to play an important role in the devel-
opment of NAS [9–11].
Due to the increased risk of complications, transplant-
ation of DCD liver grafts necessitates the development of
more qualified preservation methods than the conven-
tional SCS. Machine perfusion (MP) is a dynamic preser-
vation strategy which has been identified as a tool to
improve the quality of DCD organs [12]. One of the most
important benefits of MP compared to conventional SCS
is the ability to provide oxygen to the graft. Even at very
low temperatures such as 12 °C, liver metabolism still re-
quires oxygen [13]. Other benefits of MP are the exposure
of the endothelium to perfusion, the supply of nutrients,
and dilution of waste products. Many studies have ob-
served a reduction in ischemia-reperfusion injury (IRI)
due to MP [14, 15].
A well-studied modality of MP is end-ischemic
hypothermic oxygenated MP. It is a relatively simple
modality of MP which is performed for a short period of
two hours after conventional SCS during which the liver is
transported to the hospital of the recipient [15, 16]. Experi-
mental animal studies have demonstrated improved cellular
energy homeostasis due to end-ischemic oxygenated MP by
restoration of mitochondrial function which resulted in an
increased adenosine triphosphate (ATP) tissue concentration.
Other observed effects are reduced production of reactive
oxygen species, reduced cellular death [14–16], improved
hepatocyte function, and enhanced energy dependent bile
production after warm reperfusion [17]. Furthermore, the in-
jury to the vascular endothelium [15] and peribiliary vascular
plexus [18] is attenuated. To summarize, experimental ani-
mal studies have shown that end-ischemic hypothermic oxy-
genated MP of liver grafts after SCS reduces IRI resulting in
improved organ integrity and function after reperfusion.
Based on the excellent results in experimental studies,
end-ischemic hypothermic MP was investigated in the
clinical setting of human liver transplantation in hospi-
tals in New York, Zurich, and Groningen. These first
clinical experiences have shown that the preservation
method is safe, improves early graft function, and atten-
uates IRI as reflected by a reduction of postoperative
serum markers of liver preservation injury. Furthermore,
fewer complications such as NAS and shorter hospital
stay were observed in comparison to a retrospective
control group of patients receiving a liver preserved with
SCS alone [19–22].
Although the results of the first clinical studies are
promising, they were small cohort studies without a ran-
domized control group. The present study is a random-
ized controlled trial to determine the efficacy of two
hours of end-ischemic DHOPE prior to implantation of
a DCD (Maastricht category III) liver graft in reducing
the incidence of NAS after transplantation.
Methods
Design and objective
The DHOPE-DCD trial (dual hypothermic oxygenated
machine perfusion in donation after circulatory death
liver transplantation) is designed as a prospective, ran-
domized, controlled, multicenter, parallel-arm, inferior-
ity, clinical trial in 156 patients undergoing DCD liver
transplantation. The primary objective is to study the ef-
ficacy of end-ischemic DHOPE in reducing the incidence
of symptomatic NAS after DCD liver transplantation.
Liver grafts in the intervention group will be preserved
with SCS followed by two hours of DHOPE and liver
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grafts in the control group will be preserved by SCS
alone without any further intervention. This multicenter
trial is investigator-initiated and at least five academic cen-
ters are included, located in the Netherlands, Belgium, and
the United Kingdom. A list of study sites can be obtained
via Clinicaltrials.gov with the identifier NCT02584283
(https://clinicaltrials.gov/ct2/show/NCT02584283) where
the trial was registered in September 2015 and periodically
updated. This article concerns study protocol version 4.0, 6
September, 2018.
Study endpoints
The primary endpoint is the incidence of symptomatic
NAS at six months after DCD liver transplantation. The
diagnosis of symptomatic NAS is defined according to
all of the following criteria [23]:
– clinical signs (i.e., jaundice, cholangitis) or elevation
of cholestatic laboratory parameters in blood
samples taken during follow-up
– any irregularities or narrowing of the lumen of the
intra- or extrahepatic donor bile ducts, (isolated
strictures at the bile duct anastomosis were not
defined as NAS)
– which are diagnosed by cholangiogram (preferably
by MRCP)
– in the presence of a patent hepatic artery
demonstrated by Doppler ultrasonography and if
necessary, by computed tomography angiography
– and as assessed by the Adjudication Committee
The secondary endpoints (summarized in Table 1) are
the following:
1. The overall incidence of NAS including both
symptomatic and asymptomatic NAS.
Asymptomatic NAS is defined according to all of
the criteria for symptomatic NAS but excludes
clinical signs (i.e., jaundice, cholangitis) or elevation
of cholestatic laboratory parameters in blood
samples taken during follow-up. Patients will
undergo an MRCP at six months after transplant-
ation (time window of 15 days), unless they have
been diagnosed with NAS within 6 months after
transplantation or have been retransplanted.
2. The severity and location of NAS based on:
a. Scoring system described by Buis et al. [23]
b. Required treatment for NAS (i.e.
ursodeoxycholic acid, endoscopic stenting, or
retransplantation)
3. Graft (censored and uncensored for patient death)
and patient survival at 7 days, 1, 3, and 6 months
4. Primary non-function defined as liver failure requir-
ing retransplantation or leading to death within
seven days after transplantation without any identi-
fiable cause such as surgical problems, hepatic ar-
tery thrombosis, portal vein thrombosis, and acute
rejection [24].
5. Initial poor function which is based on a
modification of the Olthoff criteria: international
normalized ratio (INR) > 1.6 and/or serum total
bilirubin > 10 mg/dL on postoperative day 7 [25]. If
there are multiple analyses in one day, the morning
sample at around 5.00 A.M. is registered.
6. Graft function and ischemia-reperfusion injury deter-
mined by serum levels of alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline
phosphatase (AlkP), gamma-glutamyl transferase
(γGT), and total bilirubin at postoperative day 0–7
and 1, 3, and 6months. Day 0 is defined as the interval
between graft portal reperfusion and the midnight of
that day. If there are multiple analyses in one day, the
morning sample at around 5.00 A.M. is registered.
7. Hemodynamic status (blood pressure, heart rate and
vasopressor dosage) at 5 min before reperfusion, as
well as 10 and 20min after reperfusion
8. Length of initial ICU and initial hospital stay
determined in days of admission following liver
transplantation. Duration of follow-up hospital stay
Table 1 Endpoints
Primary endpoint
Symptomatic NAS
Secondary endpoint
1. Incidence of (a)symptomatic NAS
2. Severity of NAS
3. Graft and recipient survival
4. Primary non-function
5. Initial poor function
6. Serum biochemical graft function and injury
7. Hemodynamic status during reperfusion
8. ICU and hospital stay
9. Postoperative complications
10. Renal function
DHOPE group only:
11. Perfusion characteristics
12. Perfusate biochemical graft function and injury
13. Perfusate micro ribonucleic acid (miRNA)
14. Pathobiology of liver and bile duct parenchyma
15. Metabolic function, including new onset diabetes after
transplantation (NODAT)
16. Costs
17. Health related quality of life
Abbreviations: DHOPE dual hypothermic oxygenated machine perfusion, ICU
intensive care unit, NAS non-anastomotic biliary strictures
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is determined in days of hospital admission after
discharge and up to six months after liver
transplantation.
9. Postoperative complications are graded according
to the comprehensive complication index (CCI)
[26]. Special interest will be given to predefined
infectious complications and the total length of use
and cumulative doses of antibiotics.
10. Renal function which is defined as
a. Estimated glomerular filtration rate (eGFR)
according to the 4-variable Modification of Diet
in Renal Disease (MDRD) equation [27] at day 7,
and 1, 3, and 6months after transplantation. If
there are multiple analyses in one day, the morn-
ing sample at around 5.00 A.M. is registered.
b. Kidney injury is scored according to acute
kidney injury network (AKIN) and risk, injury,
failure, loss of kidney function and end-stage
kidney disease (RIFLE) criteria [28].
c. In selected centers, urinary kidney injury
markers such as kidney injury molecule (KIM)
[29], tissue inhibitor of matrix
metalloproteinases-2 (TIMP2), Insulin-like
Growth Factor Binding Protein-7 (IGFBP7), and
neutrophil gelatinase-associated lipocalin
(NGAL) will be measured in urine samples
taken at arrival in the ICU and at day 1, 3, and
5 after transplantation.
11. Perfusion characteristics during DHOPE include
flow, pressure and resistance at every fifteen minutes.
12. In selected centers, perfusate analyses will be
performed to study the dynamics of experimental
markers of tissue and mitochondrial injury. The
perfusate at the start and end of DHOPE
procedure, and every half hour in between will be
analyzed for pH, sodium, potassium, bicarbonate,
lactate, ALT, AST, AlkP, γGT, urea, total bilirubin,
thrombomodulin, high mobility group box-1
(HMBG) protein, and cytochrome C [30].
13. In selected centers, prognostication of NAS based
on miRNA’s: CDmiR-30e, CDmiR-222, CDmiR-296,
HDmiR-122 and HDmiR-148a will be determined
in perfusate.
14. In selected centers, biopsies of liver parenchyma
and bile duct, which are routinely taken during
transplantation, are also taken in this trial. The
biopsies are taken at three time points: before
DHOPE, after DHOPE, and after reperfusion at the
time of bile duct anastomosis during anesthesia.
The purpose is to underpin the histopathological
status of the liver and bile ducts in both study
groups. In addition, mechanistic research into
molecular mechanisms of injury and repair during
DHOPE will be done to identify pathophysiological
pathways that might have potential to predict
function and outcomes after transplantation.
15. Metabolic function, including new onset diabetes
after transplantation (NODAT) in the first 90 days
after transplantation. NODAT is defined according
to the WHO criteria (Report 2003 S5–20).
a. Symptoms of diabetes and random plasma glucose
≥11.1 mmol/L. Symptoms include polyuria,
polydipsia, and unexplained weight loss. OR
b. Fasting plasma glucose ≥7.0mmol/L. Fasting is defined
as no caloric intake for at least eight hours. OR
c. Two-hour plasma glucose ≥11.1 mmol/L during an
oral glucose tolerance test. The test should be
performed as described by the WHO, using a
glucose load containing the equivalent of 75 g
anhydrous glucose dissolved in water.
16. In selected centers, overall cost of treatment within
6 months (in/excluding return to work) is calculated
according to the Cost and Outcome analysis of
Liver Transplantation (COLT) study [5].
17. Health related quality of life will be determined using
an EQ-5D-3 L questionnaire obtained before trans-
plantation and at 6 months after transplantation. The
EQ-5D-3 L is a generic questionnaire and covers five
domains of health (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression).
Study population
Adult patients (≥ 18 years old) eligible for liver transplant-
ation are screened for participation in this trial. The inclu-
sion and exclusion criteria are presented in Table 2.
Randomization
Randomization is performed when a DCD donor liver be-
comes available for a patient who is eligible for the
DHOPE-DCD Trial and has given informed consent. How-
ever, the patient is only randomized when the liver is de-
finitively deemed suitable for transplantation and the rest
of the transplant team including the anesthetist is informed
about the exact starting time of the transplantation. The
randomization takes place via an online web-based tool
and is performed by trained trial personnel. It is a block
randomization which is stratified for trial site and for pa-
tients with primary sclerosing cholangitis.
Blinding
The procurement surgeon is blinded for the study group
assignment during organ retrieval. Patients are also
blinded to study group assignment. Additionally, assess-
ment of the primary endpoint is performed by the
blinded Adjudication Committee. When there is a
breach of blinding, this is described in the eCRF and the
Sponsor is notified.
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Study procedures
The timeline of study procedures are graphically pre-
sented in Fig 1.
Procurement of the donor liver (both study groups)
After circulatory death of the donor, the stand-by surgical
team performs a median laparotomy and aortic cannulation
to perfuse the abdominal organs with at least 4000ml of cold
(0–4 °C) preservation fluid, preferably Belzer UW® Cold Stor-
age Solution (Bridge-to-Life, Ltd., Northbrook, IL) (UW CS)
with 50.000 IU of heparin. The liver is procured with a seg-
ment of 5 cm circular supratruncal aorta left attached to the
coeliac trunk if possible. The portal vein and common bile
duct are kept as long as possible. After procurement the liver
is flushed via the portal vein with at least 1 l of preservation
fluid, preferably UW CS, without applying pressure. The
cystic duct is ligated and the bile ducts are flushed with pres-
ervation fluid, preferably UW CS and preferably at the donor
hospital. The gallbladder is preferably left in situ. The liver is
transported to the recipient hospital where the conventional
back table procedure is performed.
Back table (DHOPE group)
During the back table procedure, the portal vein and the
supratruncal aorta are cannulated. The supratruncal
aorta is cannulated in a manner that the hepatic artery is
not damaged due to cannulation. The side branches of
the hepatic artery are ligated or clipped during the back
table preparation. Short before connection to the ma-
chine, the liver is flushed via the portal vein cannula
with 1000mL cold (0–4 °C) Belzer MPS® UW machine
perfusion solution (Bridge-to-Life, Ltd., Northbrook, IL)
Fig. 1 Flow chart of study procedures. Abbreviations: DHOPE, dual hypothermic oxygenated machine perfusion
Table 2 Inclusion and exclusion criteria
Inclusion Exclusion
Adult patients (≥ 18 years old) Contraindication for MRCP
Donor liver from DCD (Maastricht category III) Listed for fulminant liver failure or retransplantation due to primary non-function
Donor body weight≥ 40 kg Simultaneous transplantation of another organ
Signed informed consent Incapable to give informed consent due to mental conditions
Simultaneous participation in another clinical trial that might possibly influence this trial
Recipient positive test for HIV antigen or antibody
Donor positive for HIV antigen or antibody, Hepatitis B core antibody or hepatitis B surface antigen,
or hepatitis C antibody
Abbreviations: DCD donation after circulatory death, HIV human immunodeficiency virus, MRCP magnetic resonance cholangiopancreatography
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(UW MP) until the caval effluent is clear. Normally the
back table preparation takes one hour on average.
Investigational medical device (DHOPE group)
Simultaneously with the back table procedure, the Liver
Assist (LA) is prepared for use. The LA is a dedicated ma-
chine for ex-vivo liver perfusion during storage. It is a CE
marked device (European Union Certification of Safety,
Health and Environmental Requirements) that is designed,
produced, and delivered by Organ Assist (Groningen, The
Netherlands). The LA has been used in a pilot study
(www.trialregister.nl, NTR4493, van Rijn et al. [31]) and is
currently in use in Zurich in a randomized controlled trial
in transplantation of donation after brain death (DBD) liver
grafts (clinicaltrials.gov identifier NCT01317342). The LA
enables dual perfusion via the portal vein and the hepatic
artery using two centrifugal pumps to provide a continuous
venous flow and a pulsatile arterial flow at 60 bpm. The
system is pressure controlled which allows autoregulation
of the flow through the liver, with constant pressure at
variable flow rates. The perfusion fluid can be oxygenated
by two hollow fiber membrane oxygenators and carbon di-
oxide can be removed. The temperature of the preserva-
tion fluid can be adjusted between 10 and 38 °C. The
system can be filled with any preferred perfusion fluid.
Preparation of the liver assist (DHOPE group)
The LA is prepared by connecting the disposable to the ma-
chine and filling the disposable with 4000mL ice-cold UW
MP with additional 3mmol/L glutathione (Biomedica, Fos-
cama Group, Roma, Italy). The gluthatione is a regular com-
ponent of the Belzer MPS® UW machine perfusion solution.
As gluthatione can become inactive during shelf-time, the
manufacturer recommends addition before use. The perfu-
sion pressure will be limited to a mean of 25mmHg for the
hepatic artery and 5mmHg for the portal vein. These pres-
sure settings are based on previous studies and are lower
than physiological pressures to avoid shear stress of the cold
endothelium of the hepatic vasculature [15, 18, 32]. The
temperature of the perfusion fluid will be about 12 °C when
the temperature is set to 10 °C. The thermo-unit of the LA
is filled with crushed ice in the reservoir to maintain the de-
sired temperature. The oxygen flow is set at 500mL/min of
100% oxygen on each of the two membrane oxygenators.
This flow is adequate to obtain a pO2 which has been re-
ported to be effective in increasing ATP and not harmful to
the graft [13, 33]. The LA is ready for perfusion once the set
temperature is reached and the solution is oxygenated for at
least 15min with oxygen.
Perfusion of liver (DHOPE group)
The surgeon connects the cannulas to the disposable
tubing of the LA after which the pumps of the device
are started. During the first five minutes after the con-
nection of the liver to the machine, the perfusion pres-
sure will be increased with 2 mmHg if the flow is less
than 100ml/min flow. To maintain the temperature, the
crushed ice in the reservoir of the thermo-unit must be re-
placed regularly during perfusion. A surgeon will supervise
the perfusion and will be available for trouble shooting.
Follow-up (both study groups)
During follow-up serum laboratory values which are
routinely assessed are monitored (Table 3). At 6 months
after transplantation, the patients will undergo an MRCP
and fill in the questionnaire on health related quality of
Table 3 Laboratory parameters
Donor Recipient
Baseline Follow-up
Parameter Latest before procurement Latest before transplantation Day 0–7, Month 1,3,6
Alanine aminotransferase (ALT) X X
Aspartate aminotransferase (AST) X X
Alkaline phosphatase (AlkP) X X
Gamma-glutamyl transferase (γGT) X X
Total bilirubin X X X
Lactate dehydrogenase (LDH) X X
Creatinine X X X
Potassium X X
Sodium X
International normalized ratio (INR) X X
Thrombocytes X
Glucose X
Day 0 is determined as the interval between graft portal reperfusion and the midnight of that day. If there are multiple analyses in one day, the morning sample
at around 5.00 A.M. is registered
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life (EQ-5D-3 L). The MRCP will be planned during a
routine hospital visit to the out-patient department for a
regular check-up. The MRCP will be cancelled in case the
patient has undergone retransplantation or has been diag-
nosed with symptomatic NAS before 6months of follow-up.
Usual care
Patients assigned to the control group will be transplanted
with a liver graft preserved with SCS. The patients will re-
ceive the routine health care given at participating centers.
Diagnostic and treatment decisions will not be influenced
by the trial procedures.
Data and material collection
Study data will be anonymously registered under a
unique study number in an electronic case report
form (eCRF) via a web-based tool. Patient’s name, ad-
dress and date of birth will be stored separately from
the trial data. The investigators, members of the Health
Inspection and members of the Medical Ethical Committee
(MEC) will have access to personal data. Study data and hu-
man material will be stored during 15 years. We expect that
the stored material will be valuable for future research. As-
sess to the final trial data set will be coordinated by the
Sponsor.
Statistical analysis
Power calculation
The study is powered to detect a clinically relevant differ-
ence in incidence of NAS between the two study groups.
The incidence of NAS was 29% after DCD liver trans-
plantation and 11% after DBD liver transplantation in pa-
tients transplanted in the UMCG from 2008 to 2013
(unpublished data). This incidence is similar to that re-
ported by Abt et al. (27% in DCD versus 2% in DBD trans-
plantation), Dubbeld et al. (24% versus 8%), Croome et al.
(22% versus 4%), and Meurisse et al. (33% versus 12%) [6,
34–36]. We aim to reduce the incidence of NAS after
DCD liver transplantation with DHOPE to the level ob-
served after DBD liver transplantation (absolute difference
of 29–11 = 18%). We base this presumed reduction on our
results in the pilot study in which 1 of 10 (10%) of the pa-
tients with a DHOPE treated liver developed NAS. More-
over, in other phase-1 studies of hypothermic machine
perfusion no patients developed NAS [19–22]. Based on a
power of 80% (β = 0.80) and a 5% significance level
(2-sided test) in two independent cohorts, a Chi-squared
test indicated that 77 livers were needed in each study
arm (nQuery + nInterim 3.0). Although there is a (very)
small likelihood of lost to follow-up, we still want to in-
clude an extra patient per study arm. In conclusion, the
total number of patients to be included in this study will
be 156 (77*2 + 2).
Trial sites
Participating sites are:
1. University Medical Center Groningen, Groningen,
the Netherlands
2. Erasmus University Medical Center, Rotterdam, the
Netherlands
3. Leiden University Medical Center, Leiden, the
Netherlands
4. University Hospitals Leuven, Leuven, Belgium
5. Ghent University Hospital, Ghent, Belgium
6. King’s College Hospital NHS Foundation Trust,
London, the United Kingdom
7. Queen Elizabeth Hospital Birmingham, University
Hospitals Birmingham NHS Foundation Trust,
Birmingham, the United Kingdom
Monitoring
The monitoring will be performed by qualified monitors
associated with the Trial Coordinating Center of the
UMCG or of the participating Trial Site. They will peri-
odically review whether study procedures are performed
in accordance with Good Clinical Practice (GCP) and
the study protocol with regard to informed consent,
randomization, study end points, reporting of adverse
events, etc. They will advise the Sponsor if, in its view,
the study should be terminated due to major deviations
from the study protocol.
Safety monitoring
In accordance to section 10, subsection 1, of the Wet
medisch-wetenschappelijk onderzoek (English: Law Medical
Research), the Investigator will inform the subjects and the
reviewing accredited MEC if anything occurs, on the basis
of which it appears that the disadvantages of participation
may be significantly greater than was foreseen in the re-
search proposal. The trial will be suspended pending further
review by the accredited MEC, except insofar as suspension
would jeopardize the subjects’ health. The Investigator will
take care that all subjects are kept informed.
Data safety monitoring board (DSMB)
To ensure the safeguarding of the included patients and
the expected additional burden with trial participation, a
DSMB with independent experts has been installed. The
advice(s) of the DSMB will be provided on a regular
basis after receipt, review and analysis of the interim and
final efficacy and safety data to the Sponsor and Investi-
gators and to the MEC that approved the protocol.
An interim analysis will be performed by the DSMB
after half of all patients (156/2 = 78) are included in the
trial and have completed follow-up of 6 months. The in-
terim analysis aims to determine the incidence of NAS
in the control group as a means of determining whether
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the assumption in our sample size calculation was correct:
29% patients develop NAS after DCD liver transplantation.
No statistical test will be performed unless concerns
arise about the safety of DHOPE based on the incidence
of adverse events. In that case, the Pocock sequential
boundary will be used to determine statistical significance
of adverse events between the two groups, dictating a
Z-value of 2 and thus a P-value of 0.045. The trial may be
stopped early due to: unacceptable safety concerns with
significantly more (serious) adverse events in the interven-
tion group compared to the control group and in case
new external information arises that convincingly answers
the study question or raises serious safety issues.
Reporting
All adverse events will be recorded in the eCRF and re-
ported in line listing to the MEC and the DSMB every
six months. Serious adverse events (Table 4) and sus-
pected unexpected serious adverse reactions (SUSAR)
will be reported real time to the Sponsor, the MEC, and
the DSMB. Since liver transplantation is a surgical pro-
cedure with significant morbidity, frequently occurring
complications will be exempt from real time reporting,
but will be reported only in the eCRF and every six
months in line listing.
Ethical consideration and informed consent
This trial will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki and as stated in the
laws governing human research in the participating
countries and Good Clinical Practice. The MEC of the
University Medical Center Groningen and local ethical
committees of all participating centers have approved
this protocol. This protocol was endorsed by the board
of directors of each participating hospital prior to the in-
clusion of subjects at the respective hospital.
It is important to note that absolutely no changes will
be made to national and international liver allocation
rules. The standard local liver allocation rules will be
followed. The study does not interfere or change the
process of accepting or declining a liver offered to a cer-
tain patient in any way.
Withdrawal of treatment
Subjects and Investigator can decide to terminate participa-
tion in this trial at any time for any reason, particular safety
reasons, if they wish to do so without any consequences.
Informed consent
Informed consent will be obtained by trained trial
personnel from each participating patient in oral and
written form prior to randomization. We chose to ask
eligible patients for informed consent while they are on
the waiting list or when they are placed instead of
obtaining consent when the patient is allocated a DCD
liver. By choosing this method of informed consent,
many patients will have given informed consent but will
not be included in the study because they will receive a
liver from a donation after brain death donor instead of
a DCD liver. However, we believe that it is less stressful
for patients to give consent in a stable situation when
they are listed for liver transplantation (either DCD or
DBD) at the outpatient department than when they are
summoned to the hospital for a DCD liver transplant-
ation. Therefore, the patient will be merely informed
whether they are included in the trial at the time they
are summoned to the hospital for the transplantation.
Additional burden and risk associated with trial
participation
The potential risk and burden to the patients in this trial
are minimal and are overshadowed by the potential
benefit if our hypothesis is correct: DHOPE reduces the
risk of patients developing NAS after liver transplantation.
NAS are of major impact to the patient since they often
imply a multitude of costly and debilitating interventions
and hospital admissions which may be unsuccessful and
eventually require retransplantation. Additionally, experi-
ence with DHOPE in clinical liver transplantations indi-
cate decreased preservation injury, improved organ
integrity and function, and experience with experimental
animal models showed increased survival after liver trans-
plantation in the DHOPE preserved livers.
The minimal potential risk and burden for patients in
this trial are related to the three procedures which are per-
formed merely for this trial: DHOPE itself, the MRCP and
the questionnaire about health related quality of life. Al-
though we regard the risk assessment of DHOPE as min-
imal, the risk could be associated with the timing, the
perfusion fluid, the pressure used, and the device. DHOPE
is technically a relatively easy procedure which can be per-
formed by any liver surgeon after training. As perfusion is
Table 4 Serious adverse events
Serious adverse events
Death
Graft failure (or retransplantation)
Primary non-function
Vascular complications (e.g. thrombosis) of
Portal vein
Hepatic artery
Device deficiency
Malfunction
Use errors
Which lead or could have led to serious adverse events
Unanticipated serious adverse device effects (USADEs)
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performed in the transplantation center while the recipi-
ent undergoes surgery, there is no alteration in transporta-
tion of the organ by means of conventional SCS.
The two hours of DHOPE performed at the end of
SCS will cause a minor delay in the transplantation
process because the preparation of the liver for trans-
plantation and the DHOPE perfusion will be performed
simultaneously with the recipient operation and will be
performed by an extra surgical team (Fig. 1). Normally,
preparation of the liver is performed by the surgeons
who perform the transplant operation, but this can be
performed simultaneously by another team during this
trial.
Furthermore, DHOPE is performed using a machine,
which could display technical failure during perfusion. If a
technical failure occurs, an alarm goes off and the liver
can be removed immediately from the machine by standby
surgeon within a sterile environment. It will be cooled
down in preservation fluid from 12 °C (in DHOPE) to 4 °C
as is the case in SCS. For some minutes before the liver is
cooled down, it has a metabolism of 19% instead of 11%
as is the case in SCS. There is no reason to believe that
this event will cause any significant injury to the liver
grafts because this difference in metabolism is very small,
is of short duration, and the liver is saturated with oxygen
before the perfusion failure. If the malfunctioning LA can-
not be fixed, the donor liver will be preserved in SCS until
implantation and analysis of the study results will be per-
formed as an intention-to-treat analysis: the patient will
remain in the intervention group.
Moreover the preservation fluid used is similar to the
one used in the control group. The only difference is
that the sodium and the potassium concentration ratio
are inverted. Therefore, the components that might
cause an allergic reaction in the patient receiving the
liver are no different from standard practice.
Lastly, the perfusion pressure could theoretically harm
the organ. However, the pressures used in this trial are
very low (lower than physiological) and are reported to
be used safely without causing any harm to the organ or
the vasculature [32, 37].
In the unfortunate event in which injury or death is
caused by the study, the trial centers have an insurance
policy which is in accordance with the legal requirements
and provides coverage for damage to trial participants.
Risks and burden associated with MRCP
The MRCP will be performed at six months after trans-
plantation in patients with no history of NAS or graft
loss. The risks associated with this imaging modality are
insignificant. It is a non-invasive test taking about 45
min. The MRCP will be planned on the same day that
the patient has a routine 6-month check-up in the out-
patient department to minimize patient’s traveling.
Burden associated with questionnaire
The questionnaire on health related quality of life con-
sists of 6 questions and is completed in about 5 min.
Since the questionnaire is completed twice (before trans-
plantation and at 6 months after transplantation), the
burden of the questionnaire is very low.
Discussion
DCD liver grafts are increasingly used for transplant-
ation in an attempt to overcome the organ shortage. In
the USA, transplantation of DCD livers accounted for 6%
of all liver transplantations performed in 2013, whereas in
the UK and The Netherlands as much as 33% of liver
transplantations in 2015 were performed with a DCD liver
[3, 4, 38]. The major drawback of DCD, compared to
DBD, is the inevitable period of warm ischemia which
leads to the depletion of intracellular energy sources, such
as ATP as well as other metabolic perturbations causing
cellular injury and dysfunction [39, 40]. This damage is ex-
acerbated by reperfusion injury of the liver graft and is
clinically manifested as an increased risk of complications
and graft failure after transplantation [34]. The most
troublesome complications after DCD liver transplant-
ation are biliary complications such as NAS, which have
been reported in up to 30% of the patients after DCD liver
transplantation compared to 10% in recipients of a DBD
liver graft [36, 41, 42].
This randomized controlled trial aims to study the effi-
cacy of a new preservation method, end-ischemic DHOPE,
in reducing the incidence of NAS after DCD liver trans-
plantation. End-ischemic hypothermic machine perfusion
has been studied previously in phase-1 non-randomized tri-
als in human orthotopic liver transplantation [19–22].
These first clinical experiences have provided promising re-
sults such as improved early graft function, attenuated clas-
sical biochemical markers of liver preservation injury, fewer
(biliary) complications, and shorter hospital stay in com-
parison with a retrospective control group of patients re-
ceiving a liver preserved with SCS alone.
The rationale of this study is based on the results of
the abovementioned phase-1 trials [11, 12, 16, 17]. How-
ever, these first clinical trials were cohort studies with
retrospectively selected non-randomized control groups.
Therefore, it is unwise and perhaps even unethical to ad-
just usual care as long as the clinical and health eco-
nomic benefit of DHOPE has not been demonstrated in
a randomized controlled trial.
The primary endpoint of this study is symptomatic NAS
within six months after transplantation. This clinical end-
point is selected as it is considered to reflect a relevant sign
of biliary injury caused by ischemia-reperfusion injury [8, 23].
Also, diagnostic imaging is reproducibly attainable at all
study sites and therefore can be objectified by blinded assess-
ment by the Adjudication Committee including independent
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radiologists. Moreover, the preferred imaging modality is
MRCP which is minimally invasive and is part of the routine
diagnostic work-up in case of clinical suspicion of NAS. For
the primary endpoint, the time interval of six months after
transplantation is chosen because the diagnosis of NAS is re-
ported at a median of three to four months after transplant-
ation [23, 43]. Some studies have reported an occurrence of
100% of the cases of NAS within four months [33, 43–45].
Furthermore, when NAS does develop more than 6months
following transplantation, it is less likely mediated by
ischemia-reperfusion injury [8, 46].
According to the study protocol, all patients undergo
an MRCP at 6 months after transplantation regardless
whether they have symptoms of cholestasis. This MRCP
will be assessed for biliary strictures by the blinded Ad-
judication Committee. With this standardized MRCP,
the risk of a potential bias in diagnosis rate of NAS will
be minimalized, for example when physicians would de-
liberately postpone the diagnostic imaging for NAS until
after 6 months of follow-up. Conversely, in patients with
graft failure or NAS before 6 months of follow-up, the
planned MRCP at 6 months will be cancelled.
A potential pitfall of the study is the risk of declining
the DCD liver for transplantation after randomization.
To overcome a bias due to a physicians’ preference for
either study group, the protocol stipulates randomization
after the definitive accept of the liver for transplant-
ation.. Additionally, to ensure identical procurement of
the donor liver, the surgeons performing the procure-
ment will be blinded for the study group assignment
during the organ recovery procedure.
Inclusion criteria are chosen to optimally reflect the
current clinical practice. Selective inclusion would cer-
tainly hamper the future implementation of results. For
this reason, patients with a retransplantation using a
DCD liver are included in this study. Pre-selection by
excluding patients with retransplantation would poten-
tially optimize patient outcome, but not reflect the
current clinical practice in which organ scarcity forces
clinicians to weigh waiting list time against graft quality.
Nevertheless, patients with fulminant liver failure are ex-
cluded from this trial as their high risk of complications
and mortality would potentially weaken safety monitor-
ing of the trial. Also, donors with HIV, hepatitis B, or C
are excluded from participating in order to minimize the
risk of contamination of the medical device. A similar
approach is applied in renal replacement therapy where
patients with HIV or hepatitis B or C are dialyzed with
dedicated machines to avoid contamination of non-in-
fected patients.
End-ischemic hypothermic machine perfusion is a rap-
idly developing and dynamic field with yet many still un-
answered questions. For example, there is no consensus
on the need for active oxygenation or single (portal vein)
versus dual perfusion (hepatic artery and portal vein).
Guarrera et al. were the first to report successful clinical
transplantation of extended criteria DBD donor livers
after ex situ hypothermic machine perfusion (4–6 °C) via
the portal vein and hepatic artery without active oxygen-
ation [19, 20]. Dutkowski et al. subsequently reported
that active oxygenation of the perfusion fluid adds sig-
nificantly to the benefits of hypothermic (10 °C) perfu-
sion in DCD liver transplantation [15, 19, 20, 47, 48].
Although Dutkowski’s group applied active oxygenation
of the perfusion fluid, they only perfused via the portal
vein and not via the hepatic artery. Up to present it re-
mains unclear whether dual or single perfusion is equally
effective or one method is superior to the other. How-
ever, as biliary complications are the main obstacle for
wider utilization of DCD livers and the bile ducts are
known to be predominantly vascularized through the ar-
tery, the single portal perfusion may (at least in theory)
not provide optimal preservation of the bile ducts and
their vasculature [49].
In conclusion, the DHOPE-DCD trial is a multicenter
trial designed to assess the effect of dual hypothermic
oxygenated machine perfusion compared to SCS on the
incidence of non-anastomotic biliary strictures in DCD
liver transplantation. This trial aims to improve the out-
come of patients transplanted with a DCD donor liver
by reducing the risk of NAS. Therefore, the
DHOPE-DCD trial has the potential to impact the out-
come of the individual patient by decreasing the risk of
and retransplantation. Secondly, this trial may impact the
outcome of all patients awaiting a liver transplantation be-
cause a decrease in retransplantation rate would lead to
more remaining available liver grafts for other patients. Fi-
nally, this study examines the cost-effectiveness and
budgetary impact of DHOPE against usual care for patients
with DCD liver transplantation and may affect future health
care policy concerning DCD liver transplantation.
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